Recursion Pharmaceuticals vs Iambic Therapeutics vs FutureHouse vs Tempus AI
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug di...
Visit
|
Iambic Therapeutics
San Diego AI-native drug discovery company whose Enchant platform took...
Visit
|
FutureHouse
Eric-Schmidt-backed nonprofit building AI agents to automate scientifi...
Visit
|
|
|
|---|---|---|---|---|
| RECATOOLS Score | 7 / 10 | 6.5 / 10 | 7.5 / 10 | 8.2 / 10 |
| Capability | — | — | — | |
| Value for money | — | — | — | |
| Ease of use | — | — | — | |
| ASEAN readiness | — | — | — | |
| API quality | — | — | — | |
| Pricing | Enterprise | Enterprise | Freemium | Enterprise |
| Free tier | — | — | Free public web platform and agents (Crow, Falcon, Owl, Robin) plus a free API tier for researchers. | No free tier; enterprise contracts only |
| Paid from | Partnership / collaboration deals (not a self-serve product) | Partnerships and internal pipeline (not a self-serve product) | Higher-throughput / commercial use via the Edison Scientific spinout | Custom enterprise contracts; multi-year data-licensing subscriptions (price not publicly disclosed) |
| Has API | ✗ | ✗ | ✓ | ✓ |
| Open source | ✗ | ✗ | ✗ | ✗ |
| Free to use | ✗ | ✗ | ✓ | ✗ |
| Users | — | — | — | ~50% of US oncologists; 4,500+ hospital integrations; 40M+ clinical records |
| Founded | 2013 | 2020 | 2023 | 2015 |
| Maker | Chris Gibson | Thomas Miller, Fred Manby | Sam Rodriques, Andrew White | Tempus AI, Inc. (independent, Nasdaq: TEM) |
| Verdict | What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing. Who this is for: Pharmaceutical and biotech partners, plus investors in... |
What this is for: AI-native drug discovery and development, using the Enchant platform to predict molecule properties and speed candidates to the clinic. Who this is for: Pharma and biotech partners, plus the company's... |
What this is for: Automating literature review, hypothesis generation and multi-step scientific reasoning with citation-grounded AI agents. Who this is for: Academic researchers and scientists in biology, chemistry and... |
Tempus AI sits on one of the more defensible data moats in health AI — a self-reinforcing loop of clinical sequencing, molecular data, and real-world outcomes that's hard for pure-software competitors to replicate. Q1 20... |
| Full review → | Full review → | Full review → | Full review → |
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.